Dec 30th news of New Consortium IPA has vast amounts of expertise, patented IP and the most sought after antibodies and antigens They are becoming the dominate player in this space. With this latest collaboration they have right of first refusal in any intellectual property protection and commercialization that could come out of this research.
This inhaled solution will be a treatment at onset of the disease and provide a "vaccine effect" in the patient. Everyone could be given treatment without the need for extensive diagnosis or screening with minimal skill required to adminster. Delivered directly to a person's lungs, where the Covid 19 virus infects people they are targeting in the best place possible to defeat infecting cells.
https://www.businesswire.com/news/home/20201230005075/en/